Lovastatin Tablet
Product Images NDC 68071-4955

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 68071-4955). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 4955 3)

Lovastatin 10 mg tablets packaging label from NuCare Pharmaceuticals, Inc. The label indicates 30 round white/off-white tablets engraved with CTI 141. It includes product number P0506030 and instructs the medication is Rx only. Storage instructions specify controlled temperature between 68-77°F, with warnings to keep out of reach of children. Lot, serial number, and expiration details are shown but not fully legible.*

FDA Label Image

Structural Formula (Lov00 0004 01)

Chemical structure of lovastatin, the active ingredient in the Lovastatin 10 mg oral tablet by NuCare Pharmaceuticals, Inc. The image depicts the molecular arrangement characteristic of lovastatin.*

FDA Label Image

Table I (Lov00 0004 02)

A clinical data table titled "The Effect of Other Drugs on Lovastatin Exposure When Both Were Co-administered." It lists different coadministered drugs or grapefruit juice, the number of subjects in each group, dosing details for the coadministered substances and Lovastatin, and the AUC ratio comparing Lovastatin exposure with and without the coadministered drug. The table quantifies the effect on Lovastatin exposure in various scenarios including drugs like Gemfibrozil, Itraconazole, Cyclosporine, and grapefruit juice doses.*

FDA Label Image

Figure 1 (Lov00 0004 03)

A line graph titled 'Acute Major Coronary Events (Primary Endpoint)' depicting the proportion of participants without event over years of follow-up. Two lines represent Lovastatin and Placebo groups, showing Lovastatin with a higher event-free proportion and a 37% risk reduction compared to placebo. The x-axis shows years of follow-up (0 to 6), and the y-axis shows the proportion of participants without event (0.90 to 1).*

FDA Label Image

Table Vii (Lov00 0005 04)

Data table titled 'Table VII Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis' listing interacting agents such as CYP3A4 inhibitors, HIV protease inhibitors, and others, with corresponding prescribing recommendations including contraindications, dosage limits, and avoidance advisories related to lovastatin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.